Life Sciences

  • April 17, 2026

    Kenvue Says Shea & Cocoa Butter Oil Is Accurately Labeled

    Kenvue urged a New Jersey federal court to nix a proposed class action alleging its shea and cocoa butter oil is deceptively advertised, as it's primarily made with a petroleum byproduct, arguing Thursday the front label truthfully identifies it as an oil enriched with shea and cocoa butter. 

  • April 17, 2026

    3 Key Questions On Trump's Pharma Tariffs

    President Donald Trump recently announced 100% tariffs on certain imported pharmaceutical products, with opportunities for drug companies to lower their tariff rates to zero, but questions remain about the requirements for preferential treatment and abilities to administer the regime. Here, Law360 examines three open questions surrounding pharmaceutical tariffs' implementation.

  • April 17, 2026

    AI Health Co. Illegally Shared Genetic Data, Patients Say

    A healthcare company powered by artificial intelligence violated Illinois' genetic privacy law and other consumer protection laws by compelling a genetic testing business it acquired to disclose patients' genetic information, which it then shared through data agreements with pharmaceutical giants such as Eli Lilly and AbbVie, a lawsuit in Illinois federal court says.

  • April 17, 2026

    Judge Says Biotech Co. Can't Wipe Cancer Data, For Now

    A Texas state judge signed a temporary restraining order on Friday that stops Bellicum Pharmaceuticals Inc. and the consulting firm helping it oversee its dissolution from deleting cell therapy data that the Houston-based MD Anderson Cancer Center says belongs to it.

  • April 17, 2026

    Life Sciences Firm Says Ex-VP Took Trade Secrets To Rival

    A Massachusetts life sciences startup says a former vice president who left the company last fall, purportedly to care for his ill wife, instead took trade secrets with him to a new job at a California rival.

  • April 17, 2026

    Aramark Joins NJ Insulin Pricing Suits Against PBMs

    Aramark Services Inc. joined multidistrict litigation accusing CVS and pharmacy benefit managers of colluding to inflate the price of insulin.

  • April 17, 2026

    Polsinelli Sent Bogus Infringement Letters, Suits Say

    National law firm Polsinelli PC was accused of sending letters to two medical device companies with meritless claims of patent infringement, the companies claimed in a pair of malpractice suits.

  • April 17, 2026

    Latham Leads Kailera's $625M IPO In Obesity Drug Push

    Obesity biotech Kailera Therapeutics made its public debut Friday, raising $625 million in an upsized initial public offering that represents one of the largest biotech IPOs in recent years.

  • April 17, 2026

    Doc Says Texas Man Can't Sue Over Mailed Abortion Pills

    A Texas man suing his ex-girlfriend's out-of-state doctor for prescribing mail-order abortion pills can't prove that the doctor caused the wrongful death of their unborn child, the doctor told a federal court, saying the case should be dismissed because he's not responsible for the woman's actions. 

  • April 17, 2026

    Fed. Circ. Reverses $18M Penile Implant Trade Secret Win

    In a unanimous precedential decision, the Federal Circuit on Friday largely reversed a California jury's $18.3 million trade secret verdict over a penile implant, holding that the asserted secrets were already publicly disclosed or generally known and therefore not protectable.

  • April 16, 2026

    Trump Taps Ret. Rear Admiral Schwartz As New CDC Chief

    President Donald Trump on Thursday nominated Dr. Erica Schwartz, a retired rear admiral who served in the U.S. Coast Guard and as deputy surgeon general in the first Trump administration, to be the Centers for Disease Control and Prevention's next director.

  • April 16, 2026

    Wis. Supreme Court Upholds Pabst Asbestos Verdict

    The Wisconsin Supreme Court upheld a verdict in favor of the estate of a steamfitter exposed to asbestos through his work at a Pabst Brewing Co. brewery, saying Wednesday that the company still owed a duty of care to employees of independent contractors, but capped punitive damages to about $4.65 million.

  • April 16, 2026

    Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win

    The Federal Circuit ruled Thursday that a Massachusetts federal judge was wrong to overturn a $177 million jury verdict that Teva won against Eli Lilly & Co. on headache drug patents, finding that contrary to the judge's finding, the patents are not invalid.

  • April 16, 2026

    IV Device Redesign Not Enough To Lift Ban, CBP Says

    A U.S. medical device company's redesigned products used for intravenous drips are still barred from importation into the country, U.S. Customs and Border Protection said in an order released Thursday, with the agency unconvinced the new versions aren't still patent-infringing.

  • April 16, 2026

    USPTO Ends COVID Patent Appeals Program

    The U.S. Patent and Trademark Office has decided to end a program launched five years ago that aimed to prioritize and fast-track ex parte appeals of rejections on patent applications for inventions related to combating COVID-19.

  • April 16, 2026

    Katten Partner Rejoins Epstein Becker In DC For 3rd Time

    Epstein Becker Green LLP has rehired, for the third time, a healthcare transactional attorney who focuses his practice on guiding hospital systems, private equity-backed entities and professional practices on transactional matters and regulatory compliance.

  • April 15, 2026

    Consumer Cases Drive Class Action Spike, Report Says

    Federal class action filings spiked in 2025 after nearly a decade of relative stability, fueled by a surge in consumer protection lawsuits tied to data breaches, digital commerce and online accessibility claims, according to a new report from Lex Machina.

  • April 15, 2026

    Amneal Trims But Can't Nix AGs' Drug Price-Fixing Suit

    There is enough evidence from which a jury could conclude that Amneal Pharmaceuticals participated in a conspiracy to fix the price of an epilepsy medication, but not enough to show it participated in the overarching antitrust conspiracy alleged by dozens of state attorneys general, a Connecticut federal judge ruled Wednesday.

  • April 15, 2026

    Drugmaker Aquestive's Brass Sued Over FDA Setback

    Executives and directors of pharmaceutical company Aquestive Therapeutics Inc. were hit with a shareholder's derivative suit Wednesday accusing them of ignoring deficiencies in a research study for Aquestive's allergic reaction treatment, which eventually prompted the U.S. Food and Drug Administration to reject the company's new drug application.

  • April 15, 2026

    Ex-DOJ Antitrust Atty On Google Case Joins Wilson Sonsini

    A lead attorney on the U.S. Department of Justice Antitrust Division's monopolization cases against Google LLC who left the agency last week joined Wilson Sonsini Goodrich & Rosati PC in Washington, D.C., on Wednesday as a partner.

  • April 15, 2026

    Squires Passes On 10 Patent Challenges, Takes On 2 Others

    The newest bulk order from U.S. Patent and Trademark Office Director John Squires has rejected 10 petitions for America Invents Act patent reviews while granting a couple others, including a Google challenge to a patent owned by Headwater Research LLC.

  • April 15, 2026

    NC Judge Won't Undo $4M Philips Copyright Verdict

    A North Carolina federal judge has refused to erase a $4 million jury verdict against independent service organization Transtate Equipment Co. for violations of the Digital Millennium Copyright Act, saying trial evidence provided a "firm basis" to support the jury's statutory damages award.

  • April 15, 2026

    Willkie Adds O'Melveny Litigator To Los Angeles Office

    Willkie Farr & Gallagher LLP expanded its Los Angeles office with the recent addition of a litigator who moved her practice after nearly 15 years with O'Melveny & Myers LLP.

  • April 15, 2026

    Biopharma Co. Says Ex-Worker Used Files To Build AI Rival

    A biopharmaceutical consulting firm's ex-contractor illegally downloaded thousands of proprietary internal files and emails that he then used to launch a rival company powered by artificial intelligence, the firm claimed in a lawsuit, alleging that the former contractor violated federal trade secrets law.

  • April 14, 2026

    Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told

    Hedge fund Armistice Capital and two of its executives exploited the COVID-19 pandemic to issue press releases that falsely inflated their controlling share in pharmaceutical company Vaxart, then dumped the shares for $250 million before the bottom fell out, investors told a California federal jury at the start of trial Tuesday.

Expert Analysis

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

  • Software Patents May Face New Eligibility Scrutiny

    Author Photo

    November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.

  • Opinion

    A Uniform Federal Rule Would Curb Gen AI Missteps In Court

    Author Photo

    To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.

  • Riding The Changing Winds For AI Innovations At The USPTO

    Author Photo

    As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.

  • Series

    The Law Firm Merger Diaries: Integrating Practice Groups

    Author Photo

    Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.

  • Opinion

    Supreme Court Term Limits Would Carry Hidden Risk

    Author Photo

    While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Next Steps For Orgs. Amid Updated OpenAI Usage Policies

    Author Photo

    OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.

  • Series

    Knitting Makes Me A Better Lawyer

    Author Photo

    Stretching my skills as a knitter makes me a better antitrust attorney by challenging me to recalibrate after wrong turns, not rush outcomes, and trust that I can teach myself the skills to tackle new and difficult projects — even when I don’t have a pattern to work from, says Kara Kuritz at V&E.

  • How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation

    Author Photo

    On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.

  • Series

    The Biz Court Digest: Welcome To Miami

    Author Photo

    After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.

  • Identifying And Resolving Conflicts Among Class Members

    Author Photo

    As the Fifth Circuit's recent decision in Nova Scotia Health Employees' Pension Plan v. McDermott International illustrates, intraclass conflicts can determine the fate of a class action — and such conflicts can be surprisingly difficult to identify, says Andrew Faisman, a clerk at the U.S. District Court for the Southern District of New York.

  • Adapting To A Plaintiff-Side Mindset For Patent Monetization

    Author Photo

    A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.